CURAPOD Raises ₹20 Cr in Pre-Series A Led by V3 Ventures, 3i Partners and Ideaspring Capital

CURAPOD, backed by Litemed, a Made-in-India, non-invasive and personalised pain management device, has raised ₹20 crore in its Pre-Series A round led by V3 Ventures, 3i Partners and Ideaspring Capital. The investment underscores growing confidence in CURAPOD’s clinically driven wearable technology addressing the widespread burden of musculoskeletal pain.

The capital raised will accelerate product and app enhancements, strengthen branding and marketing, expand D2C sales through marketplace launches, deepen partnerships across gyms, physiotherapy and sports medicine networks, and scale manufacturing and go-to-market operations. In parallel, the investment is expected to support sustained financial growth by improving operational efficiencies, strengthening unit economics, and setting the platform for a  5x revenue growth over the next 12 months. CURAPOD also plans to deploy a portion of the funds towards international expansion, with preparations underway for entry into Europe, supported by regulatory readiness, expanded clinical evidence, and local market development.

CURAPOD is a clinically proven pain relief device that delivers non-invasive, personalised pain management using photobiomodulation therapy, including targeted red light wavelengths. The technology works at a cellular level to help reduce inflammation, improve circulation, and support tissue repair, enabling pain relief with 30-60 minutes of daily consistent use for many users. The device is FDA-registered, and designed to support over 30 musculoskeletal conditions, including back pain, neck pain, knee pain, joint disorders, muscle stiffness, sports injuries, chronic injuries, and post-activity recovery. By offering a drug-free alternative to conventional pain management, CURAPOD combines medical-grade engineering with everyday usability.

Arjun Vaidya, Co-founder and Managing Partner, V3 Ventures, said, “Pain is a chronic problem across age groups and demographics that people don’t do much about. CURAPOD is building a differentiated solution in this massive category. What we liked best is that it’s world-class, evidence-based technology from India. The ability to deliver measurable pain relief with strong clinical validation positions the company well for scale in India and even across international markets. I see this as the Whoop/Ultrahuman for pain, and that’s what excites me.”

Subodh Toprani, Partner, 3I Partners, said, “CURAPOD’s wearable device brings clinically proven photobiomodulation therapy to customers in a simple, accessible format. Its strong evidence base, regulatory readiness, and measurable results set it apart, and the recent funding provides the resources to expand clinical reach and deepen adoption.”

Surya Maguluri, Founder & Chief Technology Officer, CURAPOD, backed by Litemed India Private Limited, said, “CURAPOD was developed to bridge the gap between conventional pain management and modern, non-invasive care. This funding supports the next phase of growth by enabling deeper clinical engagement, continued innovation, and broader access to personalised pain management solutions.”

Sri Velliyur, Co-founder & CEO, CURAPOD, backed by Litemed India Private Limited, said, “This funding marks a significant milestone in CURAPOD’s journey. Building on the strong momentum of the last 12 months, we are now focused on scaling pan-India and establishing CURAPOD as the go-to solution for everyday pain management. The capital will power expansion across manufacturing, supply chain, branding and marketing, key talent acquisition, and accelerated growth through D2C and marketplace channels.”

Naganand Doraswamy, Managing Partner, Ideaspring Capital, said, “CURAPOD is redefining how musculoskeletal pain is treated by bringing clinically proven photobiomodulation therapy into a wearable, user-friendly device. Ideaspring has been a proud backer of Litemed from its inception, and we believe the journey has just started as the company builds a wide portfolio of light-therapy–based pain relief devices for the future.”

Founded in 2022, CURAPOD focuses on developing clinically validated wearable medical devices for musculoskeletal pain management. With an emphasis on scientific evidence, regulatory compliance, and clinician-led adoption, the company continues to scale its presence in India while laying the foundation for global expansion.